PT  - JOURNAL ARTICLE
AU  - Norton, Alice
AU  - De La Horra Gozalo, Arancha
AU  - de Colombi, Nicole Feune
AU  - Alobo, Moses
AU  - Asego, Juliette Mutheu
AU  - Al-Rawni, Zainab
AU  - Antonio, Emilia
AU  - Parker, James
AU  - Mwangi, Wayne
AU  - Adhiambo, Colette
AU  - Marsh, Kevin
AU  - Bayona, Marta Tufet
AU  - Piot, Peter
AU  - Lang, Trudie
TI  - The remaining unknowns: A mixed methods study of the current and global health research priorities for COVID-19
AID  - 10.1101/2020.06.24.20138198
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.24.20138198
4099  - http://medrxiv.org/content/early/2020/07/15/2020.06.24.20138198.short
4100  - http://medrxiv.org/content/early/2020/07/15/2020.06.24.20138198.full
AB  - Introduction In March 2020 the World Health Organisation (WHO) released a Global Research Roadmap in an effort to coordinate and accelerate the global research response to combat COVID-19 based on deliberations of 400 experts across the world. Three months on, the disease and our understanding have both evolved significantly. As we now tackle a pandemic in very different contexts and with increased knowledge, we sought to build on the work of the WHO to gain a more current and global perspective on these initial priorities.Methods We undertook a mixed methods study seeking the views of the global research community to i) assess which of the early WHO roadmap priorities are still most pressing; ii) understand whether they are still valid in different settings, regions or countries; and iii) identify any new emerging priorities.Results Thematic analysis of the significant body of combined data shows the WHO roadmap is globally relevant, however, new important priorities have emerged, in particular, pertinent to low and lower-middle income countries (less resourced countries), where health systems are under significant competing pressures. We also found a shift from prioritising vaccine and therapeutic development towards a focus on assessing the effectiveness, risks, benefits and trust in the variety of public health interventions and measures. Our findings also provide insight into temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.Conclusion We hope these findings will help guide decision making across the broad research system including the multi-lateral partners, research funders, public health practitioners, clinicians and civil society.What is already known?The WHO produced a roadmap that set out the research priorities following a meeting in February, just before COVID-19 was declared a Pandemic. Now, at this point in the evolution of this novel disease across the world, and almost 6 months later, it is important to assess whether these priorities remain and if research teams in all countries across the globe agree that these are the most important question that need to be tackled within their health care setting and communities, both to mitigate this outbreak and to learn for next time.What are the new findings?Over 3,000 healthcare workers and researchers contributed to this research and their data tells us that across the globe there has been a shift in priorities and new questions have emerged, particularly from low-resourced settings. For example, there is a strong call for evidence on the relative effectiveness and optimal implementation of public health interventions in varied global settings, for social science studies to guide how to gain public trust and mitigate myths, to understand the impact on already present diseases within communities, and to explore the ethics of research within a pandemic.What do the new findings imply?The WHO roadmap is globally relevant, however, our findings also provide insight into the temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe COVID-19 Knowledge hub is supported by a grant from UK Research and Innovation (https://www.ukri.org/ Grant number: MC_PC_19073). The Global Health Network is supported by a grant from the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/ Grant number: OPP1169808). No other specific funding supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was limited to seeking the views of healthcare professionals and research staff; patients and the wider community where not involved. Therefore, this research would be considered 'minimal risk' and does not come under the definition of research involving human subjects. However, this work does still fall with our research methodology and remit for the protocol that is approved by the University of Oxford Research Ethics Committee (OxTREC) protocol number OxTREC 541-18.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be fully available without restriction. URLs/accession numbers/DOIs will be available only after acceptance of the manuscript for publication so that we can ensure their inclusion before publication.WHOWorld Health OrganisationAASAfrican Academy of ScienceTGHNThe Global Health Network